Clinical Trial Update: Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a quadruple regimen of isatuximab, carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory multiple myeloma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Kyprolis (carfilzomib)
• Pomalyst (pomalidomide)
• SARCLISA (isatuximab)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING